AI in Healthcare

FWA

Updates into the world of artificial intelligence and explore the most recent trends and developments in healthcare. 

Afleveringen

  1. 27 jun

    EchoNext clears the FDA, an ambient-AI reality check, and a privacy warning from Nature

    The week in medical AI, judged by one question: does this actually change what we do for patients? Saturday 27 June 2026. Diagnostic AI: EchoNext, among the first multi-condition cardiology AIs cleared by the FDA (23 June), reads a standard 12-lead ECG to flag six forms of structural heart disease. In its Nature validation it caught 77% of structural heart problems versus 64% for 13 cardiologists reading the same 3,200 ECGs, but it triages, it does not diagnose, and the echo still decides.Ambient AI, a reality check: in 263 clinicians across six health systems (JAMA Network Open), burnout fell from 51.9% to 38.8% in 30 days, yet time savings are modest on average and concentrate in heavy users, while the value shifts into the revenue cycle.The skeptic's corner: a new Nature paper shows medical-AI models can leak whether an individual patient was in the training data almost perfectly, even when aggregate privacy metrics look safe, and underrepresented patients are the easiest to single out.From the literature, via PubMed: two big meta-analyses on AI reading scans (breast nodal status, AUC 0.84; rectal complete response, AUC 0.85) with likelihood ratios that say adjunct, not replacement.Follow the money: once Medicare paid for AI to detect large-vessel strokes (NTAP), billed use reached about 21% by 2022, but adoption tracked the hospital, not the patient, an equity problem (AJNR).Teaching point: compared with what? Four questions before any tool changes a decision.A new episode every Saturday. Subscribe, rate the show, and send your feedback. Sources & further reading: Nature; Nature (privacy audit); European Radiology; Molecular Imaging; American Journal of Neuroradiology; JAMA Network Open; FDA; NewYork-Presbyterian / Columbia; PubMed and the National Library of Medicine.

    9 min.
  2. 20 jun

    Brain-Tumour AI Out-Diagnoses Neuropathologists, Ambient AI Grows Up, and "Compared With What?"

    The week's most important developments in medical AI, and the one question that matters: does this actually change what we do for patients? Saturday, 20 June 2026. In this episode: • Diagnostic AI. Hetairos predicts 102 methylation-defined CNS tumour subtypes from a routine H&E slide. Built and validated on 9,606 patients and 11,000+ slides across 11 centres on 4 continents; from histology alone it scored 0.87 on confident calls, and 0.68 versus 0.30 for five board-certified neuropathologists, turning a roughly 12-day molecular workup into about 12 minutes. Why molecular testing still rules, and where this really changes access. • Ambient AI grows up. Abridge expands beyond the scribe into coding, prior authorisation, claims and decision support, backed by a strategic Eli Lilly investment. Philips' Future Health Index 2026: 46% of clinicians save at least 132 hours a year, half report capacity for about 8 more patients a week, and 65% increased their AI use at work. • The skeptic's corner. Overtrust in AI medical advice, how the way you prompt can steer a model toward more accurate but also more harmful answers, and the habit that protects you: compared with what? • From the literature, via PubMed. The AMIE RCT in Nature Medicine (assisted care preferred 47% vs 33%, fewer clinically significant errors 13% vs 24%), a 70-clinician RCT in npj Digital Medicine, plus the PROTEUS AI stress-echo trial. • Follow the money. CPT 2026 adds 288 new codes including AI services (live since 1 January), NHS England commits £20m to scale AI chest X-ray, the US HHS issues an RFI on AI to cut costs, and the WHO publishes a discussion paper on AI in health policy. • The teaching point. A performance metric is a signal, not proof of benefit. A number is a signal, not a target. A new episode every Saturday. Subscribe, rate the show, and send your feedback. Sources & further reading: Nature Cancer (Hetairos); Digital Health News and Philips Future Health Index 2026; NEJM AI and Lancet Digital Health; Nature Medicine and npj Digital Medicine (via PubMed / National Library of Medicine); AMA CPT 2026; NHS England; US HHS; WHO.

    10 min.
  3. 27 apr

    AI in Healthcare -- April 27, 2026 Sandbox Regulation, Drift Mitigation, and LLM Limits

    In this week's episode of AI in Healthcare, your concise update for healthcare professionals on artificial intelligence in clinical medicine, we examine four developments from the week of April 20–27, 2026. A New England Journal of Medicine Perspective on Utah's AI-assisted prescription-renewal sandbox pilot — a state-regulated program with pharmacist-mediated escalation, distinct from the FDA pathway for software as a medical device — and the corresponding American Hospital Association governance panel on April 20. A multicenter Korean validation study in JMIR Medical Informatics introducing patient-wise recalibration to mitigate model drift in AI electrocardiography for left ventricular systolic dysfunction (reported AUC 0.956 internal, 0.940 external on follow-up pairs). A randomized controlled trial in JMIR Mental Health in which both a structured generative AI therapy chatbot and plain GPT-4o produced significant PHQ-9 reductions versus control, with no significant difference between active arms (n = 147). A methodological comparison in JMIR in which XGBoost (micro-F1 0.815) outperformed a LoRA-fine-tuned LLaMA-3 (0.780) on ASA Physical Status classification. Evidence-based, reference-linked, ~5 minutes. For healthcare professionals only. 00:00 Weekly Headlines 00:31 Utah Prescribing Sandbox 02:09 Governance Takeaways 02:38 Drift Mitigation Study 04:06 GenAI Depression Trial 05:35 LLM vs XGBoost Methods 06:48 Wrap Up and References REFERENCES Utah Prescription-Renewal Pilot. NEJM Perspective, April 2026. DOI: 10.1056/NEJMp2601148Utah Department of Commerce / Doctronic announcement, January 2026: commerce.utah.govAHA Panel — AI in Health Care: Navigating Policy, Regulation, and the Road Ahead. April 20, 2026: aha.orgLee S, Son J-W, Kim S-A, et al. Deep Learning Model Using Transfer Learning for Detecting Left Ventricular Systolic Dysfunction. JMIR Med Inform. April 24, 2026. DOI: 10.2196/83127Kuta B, Novak L, Zidkova R, et al. Effectiveness of a Fully Automated Mobile Therapeutic Versus a General Chatbot in Reducing Depression and Anxiety. JMIR Ment Health. April 22, 2026. DOI: 10.2196/82642Chen M-C, Ruan S-J, Wu J-H, Chen P-F. Classifying ASA Physical Status With a Low-Rank-Adapted Large Language Model. J Med Internet Res. April 21, 2026. DOI: 10.2196/89540  Disclaimer: For healthcare professionals only. Not medical advice. Opinions expressed do not represent any institution. #AIinHealthcare #ClinicalAI #DigitalHealth #FDA #AIRegulation #AIECG #GenerativeAI #LLM #NEJM #JMIR

    7 min.

Info

Updates into the world of artificial intelligence and explore the most recent trends and developments in healthcare.